HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
T2017-002 TACL Ixazomib Study
This study is now recruiting.
CHOP and the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium is conducting a study for children and young adults 21 years old or younger who have relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. This study adds the study drug 'Ixazomib' to standard relapsed ALL chemotherapy drugs. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT03817320" or visit the TACL website. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email [email protected].
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] chop.edu or 267-426-0762.
Eligibility & Criteria
IRB #:
19-016348
Official Title:
T2017-002 A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 Month - 21 Years
Gender:
All
Leader
